{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:42:54Z","timestamp":1791513774295,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["2021-02680"],"award-info":[{"award-number":["2021-02680"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovative Health Initiative Joint Undertaking","award":["101112145"],"award-info":[{"award-number":["101112145"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40273-024-01443-2","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T05:07:40Z","timestamp":1730437660000},"page":"153-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Costs of Care in Relation to Alzheimer\u2019s Disease Severity in Sweden: A National Registry-Based Cohort Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-4834","authenticated-orcid":false,"given":"Sandar","family":"Aye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Frisell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Borgh","family":"Skillb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Eriksdotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Aho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"1443_CR1","doi-asserted-by":"publisher","unstructured":"2022 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2022;18(4), 700\u2013789. https:\/\/doi.org\/10.1002\/ALZ.12638","DOI":"10.1002\/ALZ.12638"},{"issue":"7","key":"1443_CR2","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1002\/alz.12901","volume":"19","author":"A Wimo","year":"2023","unstructured":"Wimo A, Seeher K, Cataldi R, Cyhlarova E, Dielemann JL, Frisell O, et al. The worldwide costs of dementia in 2019. Alzheimers Dement. 2023;19(7):2865\u201373. https:\/\/doi.org\/10.1002\/alz.12901.","journal-title":"Alzheimers Dement"},{"key":"1443_CR3","unstructured":"World Health Organization. (2021). Global status report on the public health response to dementia. Geneva: World Health Organization. https:\/\/www.who.int\/publications\/i\/item\/9789240033245. Accessed 29 Apr 2024."},{"issue":"2","key":"1443_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JAD-180802","volume":"68","author":"G Paroni","year":"2019","unstructured":"Paroni G, Bisceglia P, Seripa D. Understanding the amyloid hypothesis in Alzheimer\u2019s disease. J Alzheimers Dis. 2019;68(2):493\u2013510. https:\/\/doi.org\/10.3233\/JAD-180802.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1443_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/J.JALZ.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. https:\/\/doi.org\/10.1016\/J.JALZ.2011.03.008.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1443_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(13)70044-9.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1443_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Budd Haeberlein S, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1443_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.31887\/DCNS.2000.2.2\/asschachter","volume":"2","author":"AS Schachter","year":"2000","unstructured":"Schachter AS, Davis KL. Alzheimer\u2019s diseasse. Dialog Clin Neurosci. 2000;2(2):91\u2013100.","journal-title":"Dialog Clin Neurosci"},{"key":"1443_CR9","unstructured":"Frisell O, J\u00f6nsson L, Wimo A (2023) Demenssjukdomarnas samh\u00e4llskostnader i sverige 2019. https:\/\/www.demenscentrum.se\/sites\/default\/files\/\/dokument\/FORSKNING\/demenssjukd_samhallskostn_2019.pdf. Accessed 29 Apr 2024."},{"key":"1443_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4198","author":"S Schaller","year":"2015","unstructured":"Schaller S, Mauskopf J, Kriza C, Wahlster P, Kolominsky-Rabas PL. The main cost drivers in dementia: a systematic review. Int J Geriatr Psychiatry. 2015. https:\/\/doi.org\/10.1002\/gps.4198.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"7","key":"1443_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/S10198-014-0620-6","volume":"16","author":"A W\u00fcbker","year":"2015","unstructured":"W\u00fcbker A, Zwakhalen SMG, Challis D, Suhonen R, Karlsson S, Zabalegui A, et al. Costs of care for people with dementia just before and after nursing home placement: primary data from eight European countries. Eur J Health Econ. 2015;16(7):689\u2013707. https:\/\/doi.org\/10.1007\/S10198-014-0620-6.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1443_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s41669-023-00451-w","volume":"8","author":"L G\u00f3mez Maldonado","year":"2024","unstructured":"G\u00f3mez Maldonado L, De Mora-Figueroa R, L\u00f3pez-Angarita A, Maravilla-Herrera P, Merino M. Cost of patients with Alzheimer\u2019s disease in spain according to disease severity. Pharmacoecon Open. 2024;8(1):103\u201314. https:\/\/doi.org\/10.1007\/s41669-023-00451-w.","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"1443_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40273-022-01212-z","volume":"41","author":"L J\u00f6nsson","year":"2023","unstructured":"J\u00f6nsson L, Tate A, Frisell O, Wimo A, Se LJ. The costs of dementia in Europe: an updated review and meta-analysis. Pharmacoeconomics. 2023;41(1):59\u201375. https:\/\/doi.org\/10.1007\/s40273-022-01212-z.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1443_CR14","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1177\/1471301219837776\/FORMAT\/EPUB","volume":"19","author":"D Cantarero-Prieto","year":"2020","unstructured":"Cantarero-Prieto D, Leon PL, Blazquez-Fernandez C, Juan PS, Cobo CS. The economic cost of dementia: a systematic review. Dementia (London). 2020;19(8):2637\u201357. https:\/\/doi.org\/10.1177\/1471301219837776\/FORMAT\/EPUB.","journal-title":"Dementia (London)"},{"key":"1443_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2023.09.008","volume":"40","author":"LX Tay","year":"2024","unstructured":"Tay LX, Ong SC, Tay LJ, Ng T, Parumasivam T. Economic burden of Alzheimer\u2019s disease: a systematic review. Value Health Region Issues. 2024;40:1\u201312. https:\/\/doi.org\/10.1016\/j.vhri.2023.09.008.","journal-title":"Value Health Region Issues"},{"issue":"5","key":"1443_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/gps.1489","volume":"21","author":"L J\u00f6nsson","year":"2006","unstructured":"J\u00f6nsson L, J\u00f6nhagen ME, Kilander L, Soininen H, Hallikainen M, Waldemar G. Determinants of costs of care for patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2006;21(5):449\u201359. https:\/\/doi.org\/10.1002\/gps.1489.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"1443_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/156720510791162430","volume":"7","author":"J Mesterton","year":"2010","unstructured":"Mesterton J, Wimo A, By \u00c5, Langworth S, Winblad B, J\u00f6nsson L. Cross sectional observational study on the societal costs of Alzheimer\u2019s disease. Curr Alzheimer Res. 2010;7(4):358\u201367.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"1443_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jalz.2010.09.001","volume":"7","author":"A Gustavsson","year":"2011","unstructured":"Gustavsson A, Bergvall N, Kolasa K, Wimo A, Winblad B, J\u00f6nsson L. Predictors of costs of care in Alzheimer\u2019s disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011;7(3):318\u201327. https:\/\/doi.org\/10.1016\/j.jalz.2010.09.001.","journal-title":"Alzheimers Dement"},{"key":"1443_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0215-9","author":"A Wimo","year":"2016","unstructured":"Wimo A, J\u00f6nsson L, Fratiglioni L, Sandman PO, Gustavsson A, Sk\u00f6ldunger A, Johansson L. The societal costs of dementia in Sweden 2012\u2014relevance and methodological challenges in valuing informal care. Alzheimer\u2019s Res Ther. 2016. https:\/\/doi.org\/10.1186\/s13195-016-0215-9.","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"12","key":"1443_CR20","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1002\/alz.12619","volume":"18","author":"S Persson","year":"2022","unstructured":"Persson S, Saha S, Gerdtham UG, Toresson H, Tr\u00e9pel D, Jarl J. Healthcare costs of dementia diseases before, during and after diagnosis: longitudinal analysis of 17 years of Swedish register data. Alzheimers Dement. 2022;18(12):2560\u20139. https:\/\/doi.org\/10.1002\/alz.12619.","journal-title":"Alzheimers Dement"},{"key":"1443_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-024-01707-w","author":"J Zilling","year":"2024","unstructured":"Zilling J, Gerdtham UG, Jarl J, Saha S, Persson S. The formal care costs of dementia: a longitudinal study using Swedish register data. Eur J Health Econ. 2024. https:\/\/doi.org\/10.1007\/s10198-024-01707-w.","journal-title":"Eur J Health Econ"},{"issue":"9984","key":"1443_CR22","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu T, Lehtisalo J, Solomon A, Lev\u00e4lahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(15)60461-5.","journal-title":"Lancet"},{"key":"1443_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02869-z","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler S, He Y, Janelidze S, Collij LE, et al. Highly accurate blood test for Alzheimer\u2019s disease comparable or superior to clinical CSF tests. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-02869-z.","journal-title":"Nat Med"},{"issue":"4","key":"1443_CR24","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton N, Barth\u00e9lemy N, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146(4):1592\u2013601. https:\/\/doi.org\/10.1093\/brain\/awac333.","journal-title":"Brain"},{"issue":"2","key":"1443_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/JPAD.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210. https:\/\/doi.org\/10.14283\/JPAD.2022.30.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"1443_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/nejmoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/nejmoa2212948.","journal-title":"N Engl J Med"},{"issue":"6","key":"1443_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"issue":"6","key":"1443_CR28","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/AGEING\/AFW141","volume":"45","author":"H Taipale","year":"2016","unstructured":"Taipale H, Koponen M, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S. Drug use in persons with and without Alzheimer\u2019s disease aged 90 years or more. Age Ageing. 2016;45(6):900\u20134. https:\/\/doi.org\/10.1093\/AGEING\/AFW141.","journal-title":"Age Ageing"},{"key":"1443_CR29","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/ene.13043","volume":"23","author":"S Frahm-Falkenberg","year":"2016","unstructured":"Frahm-Falkenberg S, Ibsen R, Kjellberg J, Jennum P. Health, social and economic consequences of dementias: a comparative national cohort study. Eur J Neurol. 2016;23:1400\u20137. https:\/\/doi.org\/10.1111\/ene.13043.","journal-title":"Eur J Neurol"},{"issue":"2","key":"1443_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0116538","volume":"10","author":"D Religa","year":"2015","unstructured":"Religa D, Fereshtehnejad SM, Cermakova P, Edlund AK, Garcia-Ptacek S, Granqvist N. SveDem, the Swedish Dementia Registry\u2014a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PLoS ONE. 2015;10(2):1\u201314. https:\/\/doi.org\/10.1371\/journal.pone.0116538.","journal-title":"PLoS ONE"},{"issue":"7","key":"1443_CR31","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2006","unstructured":"Wettermark B, Hammar N, Fored C, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register-Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2006;16(7):726\u201335. https:\/\/doi.org\/10.1002\/pds.1294.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1443_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011. https:\/\/doi.org\/10.1186\/1471-2458-11-450.","journal-title":"BMC Public Health"},{"issue":"7","key":"1443_CR33","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/14034948211061016","volume":"50","author":"AC Meyer","year":"2022","unstructured":"Meyer AC, Sandstr\u00f6m G, Modig K. Nationwide data on home care and care home residence: presentation of the Swedish Social Service Register, its content and coverage. Scand J Public Health. 2022;50(7):946\u201358. https:\/\/doi.org\/10.1177\/14034948211061016.","journal-title":"Scand J Public Health"},{"key":"1443_CR34","unstructured":"Cognitive impairment in suspected dementia - National clinical knowledge support. (n.d.). Retrieved 25 August 2023, from https:\/\/www.nationelltklinisktkunskapsstod.se\/kunskapsstod\/vardforlopp\/?uuid=c38fa4a0-a3ec-4b15-8aec-beca2fefe69b. Accessed 29 Apr 2024."},{"key":"1443_CR35","unstructured":"Socialstyrelsen. (2017). Nationella riktlinjer 2017. V\u00e5rd och omsorg vid demenssjukdom - st\u00f6d f\u00f6r styrning och ledning. [National guidelines for care in cases of dementia]."},{"key":"1443_CR36","unstructured":"World Health Organization. (n.d.). ICD-10 Version:2016. Retrieved 28 July 2022, from https:\/\/icd.who.int\/browse10\/2016\/en#. Accessed 29 Apr 2024."},{"issue":"10","key":"1443_CR37","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/gerona\/glw233","volume":"72","author":"A Calder\u00f3n-Larra\u00f1aga","year":"2017","unstructured":"Calder\u00f3n-Larra\u00f1aga A, Vetrano DL, Onder G, Gimeno-Feliu LA, Coscollar-Santaliestra C, Carf\u00ed A, et al. Assessing and measuring chronic multimorbidity in the older population: a proposal for its operationalization. J Gerontol A Biol Sci Med Sci. 2017;72(10):1417\u201323. https:\/\/doi.org\/10.1093\/gerona\/glw233. Accessed 29 Apr 2024.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1443_CR38","unstructured":"Socialstyrelsen. (2012). \u00c4ldre \u2013 v\u00e5rd och omsorg den 1 oktober 2012. Kommunala insatser enligt socialtj\u00e4nstlagen samt h\u00e4lso- och sjukv\u00e5rdslagen, 2012. Retrieved from http:\/\/www.socialstyrelsen.se. Accessed 29 Apr 2024."},{"key":"1443_CR39","unstructured":"Stockholms stad. (2020). St\u00f6d vid funktionsneds\u00e4ttning. Retrieved 29 April 2024, from https:\/\/funktionsnedsattning.stockholm\/olika-former-av-insatser\/stod-i-hemmet\/boendestod\/. Accessed 29 Apr 2024."},{"key":"1443_CR40","unstructured":"Socialstyrelsen. (2024). V\u00e5rd och omsorg f\u00f6r \u00e4ldre L\u00e4gesrapport 2024. Retrieved from https:\/\/www.socialstyrelsen.se\/aktuellt\/arets-lagesrapport--vard-och-omsorg-for-aldre\/. Accessed 29 Apr 2024."},{"key":"1443_CR41","unstructured":"Sveriges Kommuner och Regioner. (2023). Cost per patient, KPP. SKR. Retrieved 28 March 2024, from https:\/\/skr.se\/skr\/halsasjukvard\/ekonomiavgifter\/kostnadperpatientkpp.1076.html. Accessed 29 Apr 2024."},{"key":"1443_CR42","unstructured":"RKA. (n.d.). Kolada - en tj\u00e4nst fr\u00e5n RKA. Retrieved 26 February 2024, from https:\/\/www.kolada.se\/verktyg\/fri-sokning\/?kpis=35480,35484,41297,44440,76370,83908&years=30200,30199,30198&municipals=2328&rows=municipal,kpi&visualization=bar-chart. Accessed 29 Apr 2024."},{"issue":"8","key":"1443_CR43","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/jgs.14227","volume":"64","author":"PJ Lin","year":"2016","unstructured":"Lin PJ, Zhong Y, Fillit HM, Chen E, Neumann PJ. Medicare expenditures of individuals with Alzheimer\u2019s disease and related dementias or mild cognitive impairment before and after diagnosis. J Am Geriatr Soc. 2016;64(8):1549\u201357. https:\/\/doi.org\/10.1111\/jgs.14227.","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"1443_CR44","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt L, Sikkes SA, van den Hout A, Handels R, Bos I, van der Flier WM, et al. Duration of preclinical, prodromal and dementia Alzheimer disease stages in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15(7):888\u201398. https:\/\/doi.org\/10.1016\/j.jalz.2019.04.001.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1443_CR45","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/ALZ.13488","volume":"20","author":"AE Tate","year":"2024","unstructured":"Tate AE, Bouteloup V, van Maurik IS, Jean D, Mank A, Speh A, et al. Predicting sojourn times across dementia disease stages, institutionalization, and mortality. Alzheimers Dement. 2024;20(2):809\u201318. https:\/\/doi.org\/10.1002\/ALZ.13488.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1443_CR46","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3233\/JAD-191212","volume":"75","author":"R Robinson","year":"2020","unstructured":"Robinson R, Rentz D, Andrews J, Zagar A, Kim Y, Bruemmer V, et al. Costs of early stage Alzheimer\u2019s disease in the United States: cross-sectional analysis of a prospective cohort study (GERAS-US) 1. J Alzheimers Dis. 2020;75(2):437\u201350. https:\/\/doi.org\/10.3233\/JAD-191212.","journal-title":"J Alzheimers Dis"},{"key":"1443_CR47","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3233\/JAD-220415","volume":"91","author":"J Chandler","year":"2023","unstructured":"Chandler J, Kubisiak J. Clinical and economic assessment in early-stage dementia by severity and amyloid-status: a 5-year retrospective claims study of GERAS-US patients. J Alzheimers Dis. 2023;91:753\u201365. https:\/\/doi.org\/10.3233\/JAD-220415.","journal-title":"J Alzheimers Dis"},{"key":"1443_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-165","author":"L Schwarzkopf","year":"2012","unstructured":"Schwarzkopf L, Menn P, Leidl R, Wunder S, Mehlig H, Marx P, et al. Excess costs of dementia disorders and the role of age and gender-an analysis of German health and long-term care insurance claims data. BMC Health Serv Res. 2012. https:\/\/doi.org\/10.1186\/1472-6963-12-165.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1443_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3233\/JAD-210174","volume":"83","author":"N Sontheimer","year":"2021","unstructured":"Sontheimer N, Konnopka A, K\u00f6nig H-H. The excess costs of dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2021;83(1):333\u201354. https:\/\/doi.org\/10.3233\/JAD-210174.","journal-title":"J Alzheimers Dis"},{"key":"1443_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-03713-0","author":"A Sm-Rahman","year":"2022","unstructured":"Sm-Rahman A, Meinow B, Hyd\u00e9n LC, Kelfve S. Long-term care use among people living with dementia: a retrospective register-based study from Sweden. BMC Geriatr. 2022. https:\/\/doi.org\/10.1186\/s12877-022-03713-0.","journal-title":"BMC Geriatr"},{"key":"1443_CR51","unstructured":"Wimo A, Handels R, Elmst\u00e5hl S, Fagerstr\u00f6m C, Fratiglioni L, Isaksson U, et al. Informell och formell v\u00e5rd hos \u00e4ldre personer i ordin\u00e4rt boende\u2014f\u00f6r\u00e4ndringar och samspel \u00f6ver tid 2001\u20132015 i SNAC projektet. Nordanstig, Sverige. 2020. https:\/\/www.snac-k.se\/wp-content\/uploads\/2021\/03\/SNAC_Informell_formell_vard_2020.pdf. Accessed 29 Apr 2024."},{"issue":"5","key":"1443_CR52","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/j.1600-0447.2011.01741.x","volume":"124","author":"H Leicht","year":"2011","unstructured":"Leicht H, Heinrich S, Heider D, Bachmann C, Bickel H, van den Bussche H, et al. Net costs of dementia by disease stage. Acta Psychiatr Scand. 2011;124(5):384\u201395. https:\/\/doi.org\/10.1111\/j.1600-0447.2011.01741.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"1443_CR53","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/gps.1724","volume":"22","author":"G Nordberg","year":"2007","unstructured":"Nordberg G, Wimo A, J\u00f6nsson L, K\u00e5reholt I, Sj\u00f6lund B-M, Lagergren M, Von Strauss E. Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project-a population based study in Sweden. Int J Geriatr Psychiatry. 2007;22(7):639\u201348. https:\/\/doi.org\/10.1002\/gps.1724.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"8","key":"1443_CR54","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1177\/0898264315624899\/FORMAT\/EPUB","volume":"28","author":"\u00d6 \u00c5kerborg","year":"2016","unstructured":"\u00c5kerborg \u00d6, Lang A, Wimo A, Sk\u00f6ldunger A, Fratiglioni L, Gaudig M, Rosenlund M. Cost of dementia and its correlation with dependence. J Aging Health. 2016;28(8):1448\u201364. https:\/\/doi.org\/10.1177\/0898264315624899\/FORMAT\/EPUB.","journal-title":"J Aging Health"},{"issue":"3","key":"1443_CR55","doi-asserted-by":"publisher","first-page":"e0213787","DOI":"10.1371\/journal.pone.0213787","volume":"14","author":"E Stolz Id","year":"2019","unstructured":"Stolz Id E, Mayerl H, Va E, Sky R, Freidl W. Individual and country-level determinants of nursing home admission in the last year of life in Europe. PLoS ONE. 2019;14(3):e0213787. https:\/\/doi.org\/10.1371\/journal.pone.0213787.","journal-title":"PLoS ONE"},{"key":"1443_CR56","unstructured":"Lennarth J, P\u00e4r S. Quality and cost-effectiveness in long-term care and dependency prevention. 2017. https:\/\/aldrecentrum.se\/enskilt-dokument\/quality-and-cost-effectiveness-in-long-term-care-and-dependency-prevention\/. Accessed 29 Apr 2024."},{"issue":"4","key":"1443_CR57","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3233\/JAD-180141","volume":"64","author":"CR Beam","year":"2018","unstructured":"Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz M. Differences between women and men in incidence rates of dementia and Alzheimer\u2019s disease. J Alzheimers Dis. 2018;64(4):1077\u201383. https:\/\/doi.org\/10.3233\/JAD-180141.","journal-title":"J Alzheimers Dis"},{"key":"1443_CR58","unstructured":"Brooker D, Peel E, Erol R. Women and dementia. Alzheimer\u2019s Disease International. 2015. https:\/\/www.alzint.org\/resource\/women-and-dementia-a-global-research-review\/. Accessed 29 Apr 2024."},{"key":"1443_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286930","author":"A SM-Rahman","year":"2023","unstructured":"SM-Rahman A, Meinow B, Hyd\u00e9n LC, Kelfve S. Patterns of long-term care utilization during the last five years of life among Swedish older adults with and without dementia. PLoS ONE. 2023. https:\/\/doi.org\/10.1371\/journal.pone.0286930.","journal-title":"PLoS ONE"},{"issue":"4","key":"1443_CR60","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3233\/JAD-170102","volume":"58","author":"P Cermakova","year":"2017","unstructured":"Cermakova P, Nelson M, Secnik J, Garcia-Ptacek S, Johnell K, Fastbom J, et al. Living alone with Alzheimer\u2019s disease: data from SveDem, the Swedish Dementia Registry. J Alzheimers Dis. 2017;58(4):1265\u201372. https:\/\/doi.org\/10.3233\/JAD-170102.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"1443_CR61","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jamda.2020.01.003","volume":"21","author":"B Meinow","year":"2020","unstructured":"Meinow B, Wastesson JW, K\u00e5reholt Phd I, Kelfve Phd S. Long-term care use during the last 2 years of life in Sweden: implications for policy to address increased population aging. J Am Med Dir Assoc. 2020;21(6):799\u2013805. https:\/\/doi.org\/10.1016\/j.jamda.2020.01.003.","journal-title":"J Am Med Dir Assoc"},{"issue":"8","key":"1443_CR62","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s12603-010-0316-2","volume":"14","author":"A Wimo","year":"2010","unstructured":"Wimo A, Jonsson L, Zbrozek A. The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia. J Nutr Health Aging. 2010;14(8):685\u201390.","journal-title":"J Nutr Health Aging"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01443-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01443-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01443-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:15:18Z","timestamp":1738257318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01443-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01443-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"30 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sandar Aye has no conflicts of interest that are directly relevant to the content of this study. Oskar Frisell has no conflicts of interest that are directly relevant to the content of this study. Henrik Zetterberg has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Tobias Borgh Skillb\u00e4ck has no conflicts of interest that are directly relevant to the content of this study. Silke Kern has served at scientific advisory boards, speaker and\/or consultant for Roche, Geras Solutions, Optoceutics, Eli Lilly, Biogen and Bioarctic. Maria Eriksdotter has served as a consultant for Roche and Biogen and has given lectures in symposia sponsored by Roche. Emil Aho has no conflicts of interest that are directly relevant to the content of this study. Xin Xia has no conflicts of interest that are directly relevant to the content of this study. Bengt Winblad receives payment for participation in SAB meetings with Artery Therapeutics, AlzeCure, Alzinova and license fees for the Resource Utilisation in Dementia (RUD) instrument. Anders Wimo has received license fees for the Resource Utilization in Dementia (RUD) instrument. Linus J\u00f6nsson has received consulting fees from H. Lundbeck A\/S and license fees for the Resource Utilization in Dementia (RUD) instrument.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Open access funding provided by Karolinska Institute. The study was funded by a research grant from the Swedish Innovation Agency (Vinnova), grant number 2021-02680. This work was supported by funding from the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No\u00a0101112145 (PROMINENT). The JU receives support from the European Union\u2019s Horizon Europe research and innovation programme and\u00a0COCIR, EFPIA, EuropaBio\u00a0MedTech Europe, Vaccines Europe,\u00a0BioArctic\u00a0AB and\u00a0Combinostics\u00a0Oy. HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union\u2019s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer\u2019s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen R\u00f6nstr\u00f6ms Stiftelse, Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor, Hj\u00e4rnfonden, Sweden (#FO2022-0270), the European Union\u2019s Horizon 2020 research and innovation programme under the Marie Sk\u0142odowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme \u2013 Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). SK was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-965923, ALFGBG-81392, ALF GBG-771071), the Alzheimerfonden (AF-842471, AF-737641, AF-929959, AF-939825), the Swedish Research Council (2019-02075, 2019-02075_15), Stiftelsen Psykiatriska Forskningsfonden, Stiftelsen Demensfonden, Stiftelsen Hjalmar Svenssons Forskningsfond, Stiftelsen Wilhelm och Martina Lundgrens vetenskapsfond. The SveDem register is supported by the Swedish Association of Local Authorities and Regions. The funders had no role in the design and conduct of the study, in the analysis and interpretation of data, in the preparation of the manuscript, or in the review or approval of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LJ conceptualized and designed the study. LJ and SA managed and analyzed the data. XX helped with the analysis of comorbidity data. ME is responsible for generating the SveDem data. TS and HZ generated the CSF biomarker data. SA and OF prepared the draft manuscript. All authors reviewed the results, contributed to, and approved the final version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author's contributions"}},{"value":"The dataset is available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}